Venus Medtech – First in Vivo Application
Instituo De Cardiologia hospital completed Venibri’s in vivo application in Argentina, a breakthrough for transcatheter heart valve (THV). Venibri is the current leading pre-packaged transcatheter heart valve system that utilizes innovative dry tissue technology. The first clinical application in Argentina was marked as a milestone in THV domain. According to Mr. Zi, the CEO and founder of Venus Medtech, Venus Medtech is going to launch multiple global clinical trails in China, Brazil, India and Europeans countries.
According to Venus Medtech General Manager Zi Zhenjun, more than 200,000 TAVI procedures have been performed worldwide since the team led by Professor Alain Cribier conducted the world's first TAVI procedure in 2002 in Rouen, France. Martin Leon, Professor of Medicine at Columbia University Medical Center, said during TCT 2015 that the TAVR market is expected to surpass the coronary artery intervention market worldwide by 2025. More than 400 TAVR procedures have been performed in China since Dr. Ge Junbo from Zhongshan Hospital of Fudan University, completed China's first TAVR procedure in 2010. Venus Medtech's Venus A-Valve, with independent intellectual property rights, is the world's only transcatheter aortic valve solution meeting China Food and Drug Administration clinical requirement.
Qiming Venture Partners managing partner Nisa Leung commented, "Venus Medtech is a leading developer of innovative cardiac valve products in China. We are confident about its industry advantages in technology and resources, and are convinced that under the leadership of its seasoned management team, Venus Medtech will become a leader in the R&D of cardiac intervention therapies in China and even around the world."